Responsibility in Drug Advertising Act of 2025
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, Responsibility in Drug Advertising Act of 2025, changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Agriculture, Transportation.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H6C8047E20721480581D4CCA486BEEB45: 1. Short title This Act may be cited as the Responsibility in Drug Advertising Act of 2025.
- Section H5E0CAF3641764FD7A6D80639D3F056BC: 2. Direct-to-consumer drug advertising The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) is amended— in section 301 (21 U.S.C. 331), by adding...
- Section H5F692DCBB25147DE8C3A9116932EDC42: 506M. Direct-to-consumer drug advertising Subject to subparagraph (B), no person shall conduct direct-to-consumer advertising, including on a social media...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, Responsibility in Drug Advertising Act of 2025, changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Agriculture, Transportation
Primary Purpose
This bill, Responsibility in Drug Advertising Act of 2025, changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
In CommitteeMr. King (for himself, Mr. Kaine, and Mr. Welch) introduced …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → The Secretary identified in the operative section
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology